Evidence map›Paper›PMID 32662515›Full record

ArticleBioscience reports2020

Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.

Lei Li, Xi Chen, Lu Hao, Qiuyan Chen, Haosheng Liu, Qing Zhou

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Analysis of mScientific reports · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lei LiSchool of Biological Science and Medical Engineering, Beihang University, Beijing, China.
Xi ChenCentral Laboratory, People's Hospital of Baoan District, Shenzhen, China.
Lu HaoScience and Education Department, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, China.
Qiuyan ChenScience and Education Department, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, China.
Haosheng LiuCentral Laboratory, People's Hospital of Baoan District, Shenzhen, China.
Qing ZhouCentral Laboratory, People's Hospital of Baoan District, Shenzhen, China.
Shenzhen Bao'an District People's Hospital · CNBeihang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal cell carcinoma (RCC) is one of most common cancers with gradually increasing incidence and high mortality. Chromogenic RCC (chRCC) is the third most common histological subtype of RCC, accounting for approximately 5-7% of RCC. In our study, the transcriptome expression profile data (n=89) of chRCC, corresponding clinical data (n=113) and the somatic mutation data (n=66) were obtained from the TCGA database. We first analyzed the mutation data of chRCC patients and divided chRCC patients into high and low tumor mutation burden (TMB) groups based on the median TMB. We found that high TMB was significantly associated with worse prognosis and could promote tumor metastasis and development. Moreover, four different immune-related genes (BIRC5, PDGFRL, INHBE, IL20RB) were also identified. We found that BIRC5 was significantly overexpressed in the high TMB group and correlated with worse prognosis. The results of univariate and multivariate COX analyses demonstrated that BIRC5 (hazard ratio (HR) = 2.094) may serve as a prognostic indicator for patients with chRCC with high TMB. In addition, we identified the possible functional pathways of BIRC5 through gene set enrichment analysis (GSEA) enrichment. A positive correlation was obtained between BIRC5 and the abundance of CD4+ T cells. The results of our study revealed their correlation between the immune-related genes and clinicopathologic features as well as potential functional pathways as well as immune infiltrating cells, which may provide more data about the development of chRCC immunotherapy.

Indexed as

Antineoplastic Agents, ImmunologicalBiomarkers, TumorCarcinogenesisCarcinoma, Renal CellCD4-Positive T-LymphocytesDatasets as TopicFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsImmune Checkpoint ProteinsKaplan-Meier EstimateKidneyKidney NeoplasmsLymphocytes, Tumor-InfiltratingAntineoplastic Agents, ImmunologicalBiomarkers, TumorBIRC5 protein, humanImmune Checkpoint InhibitorsImmune Checkpoint ProteinsSurvivinchromophobe renal cell carcinomaimmunotherapyTCGAtumor mutation burden

Identifiers

PMID32662515
PMCPMC7378265
OpenAlexW3043250465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.